Here's why the Anteotech (ASX:ADO) share price is leaping 6% today

What news did this biotech company deliver today?

| More on:
Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The AnteoTech share price is rising today 
  • AnteoTech revealed the CEO of the company has resigned
  • The company's shares have fallen 67% year to date 

The AnteoTech Ltd (ASX: ADO) share price is in the green today following some news from the company.

AnteoTech shares are currently swapping hands at 10 cents, a 3.09% gain, after hitting 10.5 cents in early trading. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up 0.49% at the time of writing.

So what did Anteotech announce today?

CEO resigns

AnteoTech CEO Derek Thomson has resigned from the company. AnteoTech, based in Brisbane, developed a COVID-19 rapid antigen test (RAT) and EuGeni Reader diagnostic platform.

Thomson will serve out his six month notice period. During this time, Thomson will work with executive director Christopher Parker and the management team to continue advancing the commercial activities of the company.

Anteotech said the board is grateful for Thomson's contribution since joining the team in July 2019 and has led the company through "a period of considerable growth and development".

Commenting on the resignation, AnteoTech chair Dr Jack Hamilton said:

On behalf of the board, we wish Derek well in his future endeavours. Since he joined AnteoTech in mid 2019, the company has experienced considerable growth and its operations have diversified considerably, thanks to the work he and the senior leadership team have undertaken.

Speaking on the succession plans, Hamilton added:

The Board is committed to ensuring it secures a suitably experienced CEO candidate that can successfully drive commercialisation of our technology and capitalise on the progress made to date.

We will keep shareholders informed of progress here and with all material operational development.

Parker was recently re-appointed executive director of the company. He will take an active role supporting Thomson to ensure "critical streams" of the Life Sciences and Energy division remain on track. He previously served as CEO of the company between April 2018 and May 2019. The board has agreed to pay Parker up to $21,000 per month for this transition work.

AnteoTech is still awaiting Therapeutic Goods Administration approval for its COVID-19 rapid antigen test. The TGA has requested more data from the company to align with World Health Organisation and European Medical Device Coordination Group requirements.

Share price snapshot

The AnteoTech share price has dropped 59% in the past year. Further, it's fallen around 67% year to date and is down 47% in the past month alone.

In contrast, the broader ASX 200 Index has returned about 9% over the past 52 weeks.

AnteoTech has a market capitalisation of around $199 million based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »